Shu C Chen

US Patent:

7820671, Oct 26, 2010

Filed:

Aug 31, 2001

Appl. No.:

10/344112

Inventors:

Robert Edward Babine - Carlsbad CA, US
Shu Hui Chen - Thousand Oaks CA, US
Ivan Collado - Madrid, ES
Cristina Garcia-Paredes - Madrid, ES
John Irvin Glass - Germantown MD, US
Deqi Guo - Carmel IN, US
Ling Jin - Indianapolis IN, US
Jason Eric Lamar - Indianapolis IN, US
Nancy June Snyder - Lizton IN, US
Xicheng David Sun - Broumfied CO, US
Mark Joseph Tebbe - Zionsville IN, US
Frantz Victor - Indianapolis IN, US
Yvonne Yee Mai Yip - Indianapolis IN, US
Robert B. Perni - Marlborough MA, US
Luc Farmer - Foxborough MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K 31/497
C07D 241/02

US Classification:

5142521, 544406

Abstract:

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

US Patent:

20220380300, Dec 1, 2022

Filed:

Jul 20, 2022

Appl. No.:

17/869116

Inventors:

- Valby, DK
Anette Graven Sams - Vaerlose, DK
Xiaofang Wang - Shanghai, CN
Debasis Das - Shanghai, CN
Jian Hong - Shanghai, CN
Shu Hui Chen - Calabasas CA, US

Assignee:

H. Lundbeck A/S - Valby

International Classification:

C07C 235/06
A61P 25/08
A61P 25/06
A61P 25/04
A61P 25/24
A61P 25/22
A61P 25/28
A61P 25/18
C07C 235/08
C07C 235/26

Abstract:

The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

US Patent:

20220280455, Sep 8, 2022

Filed:

Jul 30, 2020

Appl. No.:

17/631762

Inventors:

- Valby, DK
Mario Rottlãnder - Greve, DK
Xiaofang Wang - Shanghai, CN
Debasis Das - Shanghai, CN
Jian Hong - Shanghai, CN
Shu Hui Chen - Calabasas CA, US
Jesper Frank Bastlund - Valby, DK
Jelena Ivkovic - Valby, DK
Karina Krøjer Søby - Valby, DK
Morten Grupe Larsen - Valby, DK

Assignee:

H. Lundbeck A/S - Valby

International Classification:

A61K 31/165

Abstract:

The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

US Patent:

20210032196, Feb 4, 2021

Filed:

Jul 30, 2020

Appl. No.:

16/943872

Inventors:

- Valby, DK
Xiaofang Wang - Shanghai, CN
Debasis Das - Shanghai, CN
Jian Hong - Shanghai, CN
Shu Hui Chen - Calabasas CA, US
Anette Graven Sams - Vaerlose, DK
Krestian Larsen - Ringsted, DK

International Classification:

C07C 235/08
C07C 255/44

Abstract:

The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

US Patent:

20200172474, Jun 4, 2020

Filed:

Feb 4, 2020

Appl. No.:

16/781106

Inventors:

- Valby, DK
Anette Graven Sams - Vaerlose, DK
Xiaofang Wang - Shanghai, CN
Debasis Das - Shanghai, CN
Jian Hong - Shanghai, CN
Shu Hui Chen - Calabasas CA, US

International Classification:

C07C 235/06
A61P 25/18
A61P 25/28
A61P 25/22
A61P 25/24
A61P 25/04
A61P 25/06
A61P 25/08
C07C 235/26
C07C 235/08

Abstract:

The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

US Patent:

20190256456, Aug 22, 2019

Filed:

Feb 20, 2018

Appl. No.:

15/899843

Inventors:

- Valby, DK
Anette Graven Sams - Vaerlose, DK
Xiaofang Wang - Shanghai, CN
Debasis Das - Shanghai, CN
Jian Hong - Shanghai, CN
Shu Hui Chen - Calabasas CA, US

International Classification:

C07C 235/06
A61P 25/08
A61P 25/06
A61P 25/18
A61P 25/24
A61P 25/22
A61P 25/28
A61P 25/04

Abstract:

The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.

Address:

13916 28 Rd APT 5A, Flushing, NY 11354

Phone:

9178851871

VIN:

WDDGF8BB6CR192895

Make:

MERCEDES-BENZ

Model:

C-CLASS

Year:

2012